Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the market benchmark index within the next six months [7][18]. Core Insights - The company reported a revenue of $161 million for the first half of 2025, representing a 33% year-over-year increase, and a net profit of $15 million, which is a significant increase of 363% [2][3]. - The number of cases handled reached 225,800, marking a 47.7% increase compared to the previous year [2][3]. - The international expansion strategy is proving effective, with overseas case numbers increasing by 103.5% to 117,200, accounting for 51.9% of total cases [4][5]. Financial Performance - The overall gross margin for the first half of 2025 was 62.4%, remaining stable year-over-year, while the net profit margin improved to 9.1%, an increase of 6.5 percentage points [6]. - Domestic operations also showed steady growth, with 109,000 cases (+14%) and revenue of $90 million (+0.7%), alongside a net profit of $17 million (+52%) [5][6]. - The company completed a strategic investment in Shuyaqi in July 2025, aiming to enhance market penetration in lower-tier cities through cost-effective products and an extensive clinic network [5]. Profit Forecast and Investment Recommendations - The profit forecast for the company has been slightly adjusted downwards, with expected net profits of 86 million, 150 million, and 278 million yuan for 2025, 2026, and 2027 respectively [7]. - The company is positioned as a leading player in the domestic invisible orthodontics market, with strong brand and product capabilities, and is accelerating its overseas market breakthroughs [7].

Investment Rating - The report initiates coverage with a "Buy" rating for Grand Pharmaceutical (0512.HK) [7]. Core Views - Grand Pharmaceutical is positioned as a leading player in the nuclear medicine and high-end formulation sectors, with a comprehensive pipeline and a focus on innovative drug development. The company is expected to achieve significant growth driven by its nuclear medicine products and a robust traditional pharmaceutical segment [6][7]. Summary by Sections 1. Innovation Leading Nuclear Medicine Development - The company has established a comprehensive industrial chain covering research, production, and commercialization in nuclear medicine and precision intervention fields [11]. - Grand Pharmaceutical's core product, Yttrium-90 microsphere injection (易甘泰®), is the first approved nuclear medicine for liver cancer treatment in China, with a significant market presence [11][14]. - The nuclear medicine segment is expected to grow rapidly, with projected sales of 500 million HKD in 2024, reflecting a year-on-year increase of 140% [6]. 2. Nuclear Medicine Pipeline Entering Harvest Phase - The global nuclear medicine market is projected to grow at a compound annual growth rate (CAGR) of 16.4%, reaching 21.9 billion USD by 2029 [6][25]. - The company has a rich pipeline with 12 clinical candidates, including four in Phase III trials, targeting various cancers such as prostate and kidney cancer [6][11]. - The report highlights the potential of STC3141, a novel treatment for sepsis, which has shown significant efficacy in clinical trials [6][7]. 3. Financial Performance and Forecast - The company achieved a revenue of 61.1 billion HKD in the first half of 2025, with a year-on-year growth of 1.0%, while the net profit was 11.7 billion HKD, down 26.1% year-on-year [14][18]. - The report forecasts net profits of 20.21 billion HKD, 23.47 billion HKD, and 27.56 billion HKD for 2025, 2026, and 2027, respectively, with corresponding price-to-earnings (P/E) ratios of 17, 14, and 12 [7][14]. - The traditional pharmaceutical segment remains stable, contributing 63% of total revenue, with key products in respiratory and critical care showing solid growth [18][20]. 4. Competitive Positioning - Grand Pharmaceutical's valuation is attractive, with a 2025 P/E ratio of 17, lower than the average of comparable companies at 22 [7]. - The company has established a global sales network covering over 50 countries, demonstrating its international competitiveness [22][24]. - The report emphasizes the strategic acquisitions and partnerships that have strengthened the company's market position and product offerings [11][22].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][9] Core Views - The company's performance in the first half of 2025 met expectations, with revenue of 1.495 billion yuan (+9.52%) and net profit attributable to shareholders of 152 million yuan (+41.9%) [3][9] - The offline business showed steady growth, with a revenue increase of 11.1% to 1.37 billion yuan, driven by new acquisitions and existing business growth [5] - The company is actively embracing AI technology, having launched its first "National Medicine AI Avatar" in June 2025, with a total of 10 avatars covering eight core traditional Chinese medicine specialties by August [8][9] Financial Performance - The company achieved a gross profit margin of 30.6% (+1.2 percentage points) and a net profit margin of 10.1% (+2.3 percentage points) in the first half of 2025 [6] - The company has expanded its network to 83 medical institutions across 20 cities in China, with one institution in Singapore as of June 30, 2025 [7] - The adjusted net profit for 2025 is forecasted at 398 million yuan, with subsequent years projected at 492 million yuan in 2026 and 588 million yuan in 2027 [9][10] Market Outlook - The demand for traditional Chinese medicine services is strong, supported by favorable policies, indicating a period of rapid growth for the industry [9] - The company is positioned as a leading chain in the traditional Chinese medicine service sector, with significant long-term growth potential due to its brand, talent, and resource advantages [9]

证券研究报告·海外公司点评·旅游及消闲设施(HS) 携程集团-S（09961.HK） 2025Q2 业绩点评：利润及回购好于预期，国 际业务继续高增 买入（维持） | [盈利预测与估值 Table_EPS] | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 44,510 | 53,294 | 61,074 | 68,403 | 75,078 | | 同比（%） | 122.12 | 19.73 | 14.60 | 12.00 | 9.76 | | 归母净利润（百万元） | 9,918 | 17,067 | 26,528 | 19,074 | 21,156 | | 同比（%） | 606.91 | 72.08 | 55.44 | (28.10) | 10.91 | | Non-GAAP 净利润（百万元） | 13,071 | 18,041 | 18,334 | 20,050 | 22,043 | | 同比（%） | 910.12 | 38.02 | 1.62 | 9.36 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][4][12] Core Views - The company reported a 30.7% year-on-year increase in net profit for H1 2025, achieving a revenue of 4.108 billion yuan (up 16.0% year-on-year) [4][5] - The main brand, Han Shu, continues to lead the market, while multiple brands are contributing to long-term growth [4][5] - The company maintains its profit forecast, expecting net profits of 1.006 billion, 1.258 billion, and 1.532 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 2.53, 3.16, and 3.85 yuan [4][8] Financial Summary - Revenue for 2023 was 4.191 billion yuan, projected to grow to 8.496 billion yuan in 2025, reflecting a year-on-year growth of 25.1% [8] - Net profit for 2023 was 461 million yuan, expected to reach 1.006 billion yuan in 2025, indicating a year-on-year growth of 28.8% [8] - The gross margin is projected to remain stable at around 75.8% in 2025, with a net margin of 12.2% [8] - The company’s P/E ratio is expected to decrease from 33.1 in 2025 to 21.8 by 2027, indicating improving valuation [8]

Investment Rating - The report assigns a "Buy" rating for Alibaba Group (09988.HK) with a target price of HK$ 150 [1][7]. Core Insights - Alibaba's Q1 FY2026 revenue reached RMB 247.65 billion, showing a year-over-year increase of 2%. Adjusted EBITDA was RMB 45.74 billion, down 11% year-over-year, while non-GAAP net profit was RMB 33.51 billion, down 18% year-over-year. The performance met market expectations, maintaining the "Buy" rating [7]. - The company's investment in instant retail is beginning to yield results, with e-commerce growth aligning with market expectations. Despite a slight decline in profits due to competition, Alibaba's performance outpaced rivals like Meituan and JD.com [9]. - The cloud intelligence segment reported revenue of RMB 33.4 billion, a 26% year-over-year increase, driven by growth in public cloud services and AI product adoption. Profitability in this segment improved, with a profit margin of 8.8% [9]. - Capital expenditures for FY26Q1 were RMB 38.6 billion, a significant increase of 224% year-over-year, reflecting ongoing investments in AI and cloud services. The company plans to invest RMB 380 billion in AI over the next three years [9]. Summary by Sections Company Overview - Industry: Retail [2] - H-Share Price (as of 2025/08/29): HK$ 115.70 [2] - Market Capitalization: RMB 193.66 billion [2] - Major Shareholder: JPMorgan Chase & Co. (3.57%) [2] Financial Performance - Q1 FY2026 Revenue: RMB 247.65 billion, YOY +2% [7] - Adjusted EBITDA: RMB 45.74 billion, YOY -11% [7] - Non-GAAP Net Profit: RMB 33.51 billion, YOY -18% [7] E-commerce and Cloud Business - Instant retail revenue: RMB 14.8 billion, YOY +12% [9] - Daily average orders for instant retail: 120 million in July, 80 million in August [9] - Cloud intelligence revenue: RMB 33.4 billion, YOY +26% [9] Capital Expenditure and Future Outlook - FY26Q1 Capital Expenditure: RMB 38.6 billion, YOY +224% [9] - Planned AI investment over three years: RMB 380 billion [9] - Profit forecasts for FY2026-2028: RMB 116.33 billion, RMB 139.39 billion, RMB 160.77 billion respectively [11].

Investment Rating - The report assigns a "Buy" rating to Weichai Power (2338 HK) with a target price of HKD 20.50, indicating a potential upside of 25.8% from the current price of HKD 16.30 [1][7][11]. Core Insights - Weichai Power's 1H25 performance was stable, with revenue of RMB 113.15 billion, a year-on-year increase of 0.6%. The net profit attributable to shareholders was RMB 56.43 billion, a decrease of 4.4% year-on-year. The company expects strong growth from its M series large-bore engines and data center engines, driven by increasing demand in these segments [2][8]. - The company is experiencing significant growth in its large-bore engine sales, with over 5,000 units sold, representing a 41% year-on-year increase. The sales of new energy heavy trucks surged by 255% year-on-year, with over 10,000 units sold [8]. - The report highlights the acceleration of overseas business expansion, with new orders from Kion Group amounting to EUR 6.21 billion in 1H25, setting a new quarterly record in 2Q25 [8]. Financial Overview - Revenue projections for Weichai Power are as follows: RMB 213.96 billion in 2023, RMB 215.69 billion in 2024, and RMB 237.92 billion in 2025, reflecting a compound annual growth rate (CAGR) of approximately 10.3% from 2024 to 2025 [3][13]. - The net profit is expected to grow from RMB 9.01 billion in 2023 to RMB 14.64 billion in 2025, with a significant year-on-year growth rate of 28.4% in 2025 [3][13]. - The report indicates a projected dividend yield of 6.5% in 2025, with a payout ratio expected to increase to 60% in the future, providing a strong safety margin for investors [8]. Market Position and Competitive Advantage - Weichai Power holds an estimated market share of 9-10% in the domestic data center engine market, with significant growth potential due to the increasing demand for AI data centers and the domestic replacement of foreign products [8]. - The company benefits from a short supply cycle, product reliability, and strong product capabilities, which are expected to enhance its market share in the high-margin large-bore engine segment [8].

房地产开发 Email：youzp@zts.com.cn 执业证书编号：S0740523080001 Email：houxd@zts.com.cn | 基本状况 | | | --- | --- | | 总股本(百万股) | 2,539.60 | | 流通股本(百万股) | 2,539.60 | | 市价(港元) | 9.76 | | 市值(百万港元) | 24,786.48 | | 流通市值(百万港 | 24,786.48 | | 元) | | 1、《短期业绩承压，积极布局核心 城市》2025-04-25 执业证书编号：S0740523020005 股价与行业-市场走势对比 结算节奏及减值影响当期利润。2025 年上半年，公司实现营收 533.7 亿元，同比-23. 3%，股东应占利润为 2.1 亿元，同比-89.7%。收入和利润下滑，一方面系项目结算 分布不均，结算面积同比-22.7%，另一方面，房地产市场环境转冷，公司计提了 19. 3 亿元的资产减值。总体来看，在行业基本面下滑的背景下，公司在财务上较为保守， 充分计提减值，为未来轻装上阵打下良好的基础。 销售排名前列，拿地聚焦核心城市。2025 年上半 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.08 [1][5] Core Views - Despite short-term profit pressure, the company's development business scale and operational advantages remain industry-leading, with a stable market share in development business [1][2] - The company plans to launch 24 new projects in key cities in the second half of the year, supported by ample and high-quality land reserves, which is expected to provide solid support for sales recovery [1][3] - The overall performance is under pressure due to the adjustment in the real estate industry, but non-development business shows resilient growth [2][4] Summary by Sections Financial Performance - In the first half of 2025, the company reported revenue of RMB 83.2 billion, down 4% year-on-year, and a net profit attributable to shareholders of RMB 8.6 billion, down 17% year-on-year, which is below previous annual growth expectations of -6% [1][2] - The revenue from development business decreased by 5% to RMB 78 billion, with a gross profit margin of 15.8%, down 0.5 percentage points from 2024 [2] Market Position - The company achieved a total contract sales amount of RMB 120.2 billion in the first half of 2025, ranking second in the industry, with first place in 14 cities and top three in 31 cities [3] - The company acquired 17 new land parcels during the period, with a total land acquisition amount of RMB 40.4 billion, up 213% year-on-year, maintaining a focus on core areas [3] Financing and Cost Management - As of the end of the first half of 2025, the company had interest-bearing liabilities of RMB 227.5 billion, down 5.8% quarter-on-quarter, with a cash-to-short-term debt ratio of 4.9 times [4] - The average financing cost for the first half of 2025 was 2.9%, and the sales and administrative expense ratio was 3.8%, both remaining at industry low levels [4] Profit Forecast and Valuation - The company has adjusted its revenue and gross margin assumptions for 2025-2027, with EPS estimates revised to RMB 1.39, RMB 1.48, and RMB 1.60 for the respective years [5] - The target price of HKD 19.08 is based on a price-to-book ratio (PB) of 0.49 times, consistent with comparable companies [5]

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company reported a revenue of $199 million in Q2 2025, representing a year-over-year increase of 8.5%, while operating profit decreased by 56.5% to $3.7 million due to increased labor costs [1][2] - The company aims to enhance customer experience and employee satisfaction, which may temporarily affect operating profit margins but is expected to strengthen the brand and improve operational quality in the long term [1][3] - The company is expanding its store network while focusing on quality, with a total of 126 stores operational as of Q2 2025, including new openings in Malaysia [3] - The company has adjusted its profit forecasts for 2025-2027, lowering the adjusted net profit estimates by 43%, 21%, and 17% to $30 million, $52 million, and $68 million respectively [4][10] Summary by Sections Financial Performance - Q2 2025 revenue was $199 million, with a year-over-year growth of 8.5%, and a net profit of $16 million, marking a turnaround from losses due to reduced foreign exchange losses [1][2] - For the first half of 2025, revenue reached $397 million, up 7% year-over-year, with a net profit of $28 million [1] Operational Insights - Same-store sales increased by 5.3% in Q2 2025, with notable performance in East Asia, particularly Japan [2] - The company has introduced a more value-oriented menu, resulting in a gross margin of 66.0%, slightly down by 0.3 percentage points year-over-year [2] Expansion Strategy - The company is actively pursuing its "Pomegranate Plan" to diversify its offerings and enhance customer experience, with over 10 new project tracks identified for future growth [3] - The company plans to continue exploring new markets and types of cuisine, including barbecue and fast food, to establish a second growth curve [3] Profit Forecast and Valuation - The adjusted net profit estimates for 2025-2027 have been revised downwards due to increased operational costs, with a target price set at HKD 17.46, based on a 28x PE ratio for 2026 [4][10] - The company is expected to maintain a gross margin of around 67% in the coming years, despite slight adjustments due to rising labor costs [10][14]